Phase III, randomised, multicenter study to assess the efficacy and safety of HuM195 (recombinant humanized anti-CD33 monoclonal antibody) in combination with standardized chemotherapy compared to standardized chemotherapy alone in the treatment of patients with refractory or first-relapsed acute myelogenous leukemia (AML).

Trial Profile

Phase III, randomised, multicenter study to assess the efficacy and safety of HuM195 (recombinant humanized anti-CD33 monoclonal antibody) in combination with standardized chemotherapy compared to standardized chemotherapy alone in the treatment of patients with refractory or first-relapsed acute myelogenous leukemia (AML).

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Feb 2010

At a glance

  • Drugs Cytarabine; Etoposide; Lintuzumab; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 11 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top